The only approved treatments for Alzheimer’s disease are medications with limited effectiveness and a risk of severe, sometimes deadly, side effects. Researchers found that when the device was aimed at the right spot in the brain, it could slow the development of symptoms, such as memory loss, compared to an inactive treatment. In Alzheimer’s, nerve cells in the brain at some point start to dysfunction, leading to the debilitating symptoms of memory loss. What’s more, during the yearlong TMS trial, participants receiving the experimental treatment showed little decline in their abilities to perform the activities of daily living. Sinaptica’s weekly brain stimulation therapy is intended to strengthen connections in areas of the brain that control memory.

---

Persons: Giacomo Koch, ” Koch, Koch, Irina Skylar, Scott, “, ”, Lawrence Honig, Honig, Ryan Darby, Darby Organizations: University of Ferrara, Sinaptica, NBC News, TMS, Alzheimer’s Association, Food and Drug Administration, Stanford University’s Center, Memory Disorders, Columbia University Irving Medical Center, Vanderbilt University Medical Center Locations: Madrid, Cambridge , Massachusetts, U.S